Compare Citius Pharmaceuticals Inc (CTXR) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Mercadolibre Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Mercadolibre Inc trades at $1,861 (market cap $94.13B). The key difference: Mercadolibre Inc is far larger — about 6911.2× Citius Pharmaceuticals Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Mercadolibre Inc for 117 Days on average.
| CTXR | MELI | |
|---|---|---|
Market Cap | $13.62M | $94.13B |
Volume | 132,438 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $2.36K |
52-Week Low | $0.48 | $1.55K |
Typical Hold Time | 16 Days | 117 Days |
Enterprise Value | $3.79M | $101.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
MercadoLibre (MELI) trades at $1,868.01, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $28.89 billion in 2025, though net income margin compressed to 6.91%. Recent news highlights expansion in Brazil's delivery and pharmacy segments, while analyst consensus remains strongly bullish with a $2,170 price target.
MELI's integrated e-commerce and fintech ecosystem in Latin America presents significant growth potential, supported by expanding credit portfolios and advertising revenue. Key risks include macroeconomic pressures in Argentina and margin compression from increased investment. With 73% analyst buy ratings and institutional accumulation, the stock offers growth exposure but requires monitoring of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
